Budtz-Lilly Jacob, Wanhainen Anders, Eriksson Jacob, Mani Kevin
Section of Vascular Surgery, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Section of Vascular Surgery, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
J Vasc Surg. 2017 Nov;66(5):1349-1356. doi: 10.1016/j.jvs.2017.03.422. Epub 2017 Jun 21.
This study reports the feasibility of adopting a total endovascular approach for the treatment of complex abdominal aortic aneurysms (AAAs) at a European aortic center and compares the short- and midterm results against those from large and multicenter studies.
All patients treated endovascular aortic repair (EVAR) for juxta/pararenal AAAs or thoracoabdominal aortic aneurysms (TAAAs), both elective and acute, as well as reoperations, from 2010 to 2015 were included. Treatment was fenestrated (FEVAR) or branched (BEVAR), and outcomes were analyzed for technical success and mortality at 30 and 90 days and by Kaplan-Meier curve estimates at 3 years. Outcomes on target vessels were reported as freedom from branch instability in the follow-up period. Reinterventions, endoleaks and perioperative and postoperative morbidities were analyzed.
A total of 71 patients were treated for juxta/pararenal AAA (n = 40) or TAAA (n = 31): 14 type II, 4 type III, and 13 type IV. There were 47 FEVAR (including 2 physician-modified fenestrated grafts) and 24 BEVAR procedures performed. Four TAAAs were ruptured. No open repairs were performed for these pathologies in this period. Mortality was 2.8% (n = 2) at 30 days and 9.9% at 90 days (n = 7). One late rupture occurred in a patient whose treatment was a technical failure. Survival at 3 years was 77.9% ± 5.6% overall, 90.9% ± 5.2% for juxta/pararenal AAAs, and 60.7% ± 10.3% for TAAAs. Graft deployment was successful in 69 of 71 patients. Revascularization was successful in 205 of 208 target vessels (98.6%): 51 of 51 superior mesenteric arteries, 27 of 27 celiac arteries, and 127 of 130 renal arteries. There were 131 fenestrated bridging stent grafts and 74 branched bridging stent grafts. Technical success was 68 of 71 (95.7%). There were nine cases of branch instability (5 BEVARs, 4 FEVARs) in five patients (7.0%). Seven vessels (5 renal arteries and 2 superior mesenteric arteries) underwent reintervention: 5 for stenoses, 1 for occlusion, and 1 for stent migration. Freedom from branch instability at 3 years was 92.7% ± 2.5% overall, 88.6% ± 6.4% for BEVAR, and 94.6% for FEVAR.
The short- and midterm results obtained here indicate that the benefits of a total endovascular treatment for complex aortic aneurysms, as demonstrated by large and multicenter studies, can be adapted and replicated at other centers with a dedicated aortic service. This may help guide future considerations of how to refer or treat this complex patient group.
本研究报告了在欧洲一家主动脉疾病治疗中心采用全腔内治疗方法治疗复杂腹主动脉瘤(AAA)的可行性,并将短期和中期结果与大型多中心研究的结果进行比较。
纳入2010年至2015年期间接受腔内主动脉修复术(EVAR)治疗的近肾/肾周AAA或胸腹主动脉瘤(TAAA)患者,包括择期和急诊手术患者以及再次手术患者。治疗方式为开窗(FEVAR)或分支(BEVAR),分析30天和90天时的技术成功率和死亡率,并通过Kaplan-Meier曲线评估3年生存率。报告随访期间目标血管无分支不稳定的情况。分析再次干预、内漏以及围手术期和术后并发症。
共有71例患者接受了近肾/肾周AAA(n = 40)或TAAA(n = 31)治疗:14例II型,4例III型,13例IV型。共进行了47例FEVAR(包括2例医生改良的开窗支架移植物)和24例BEVAR手术。4例TAAA破裂。在此期间,这些疾病未进行开放修复手术。30天时死亡率为2.8%(n = 2),90天时为9.9%(n = 7)。1例患者术后晚期破裂,其治疗属于技术失败。3年总体生存率为77.9%±5.6%,近肾/肾周AAA为90.9%±5.2%,TAAA为60.7%±10.3%。71例患者中有69例成功植入移植物。208条目标血管中有205条血管血运重建成功(98.6%):51条肠系膜上动脉中的51条,27条腹腔干动脉中的27条,130条肾动脉中的127条。使用了131个开窗桥接支架移植物和74个分支桥接支架移植物。技术成功率为71例中的68例(95.7%)。5例患者(7.0%)出现9例分支不稳定(5例BEVAR,4例FEVAR)。7条血管(5条肾动脉和2条肠系膜上动脉)接受了再次干预:5条因狭窄,1条因闭塞,1条因支架移位。3年时无分支不稳定的比例总体为92.7%±2.5%,BEVAR为88.6%±6.4%,FEVAR为94.6%。
本研究获得的短期和中期结果表明,大型多中心研究所证明的复杂主动脉瘤全腔内治疗的益处,在其他拥有专门主动脉疾病治疗服务的中心可以适用和复制。这可能有助于指导未来对于如何转诊或治疗这一复杂患者群体的思考。